

## **ENDOCYTE SIGNS LICENSING AGREEMENT FOR SANGSTAT'S COMPLEXINE TECHNOLOGY**

### **Complexine Technology Licensed for Vitamin-Based Cancer Therapeutics**

FREMONT, California and WEST LAFAYETTE, Indiana — October 1, 2001 — SangStat (**Nasdaq:SANG**) and Endocyte Inc. announced today that they have signed an agreement that grants Endocyte a nonexclusive, worldwide license to commercialize vitamin-based treatments using SangStat's complexine technology. The agreement also allows Endocyte the right to sub-license the technology. Financial terms include license fees and royalties on sales.

By combining targeting and immunostimulatory (effector) moieties, the complexine technology directs an immune response to a specific site, such as a solid tumor, to neutralize or interfere with its growth.

Endocyte presently focuses on the use of the vitamin folate in both the early diagnosis and therapeutic treatment of cancer. With access to SangStat's complexine technology, Endocyte will pursue development and commercialization of its folate-targeting cancer therapeutics. The company is currently in phase I and II clinical trials with in vivo, solid tumor diagnostics that use folate-targeting of radioactive labels in identifying ovarian cancers. The folate receptor is selectively expressed in over 90 percent of ovarian cancers, and low survival in ovarian cancer patients is, to a large degree, due to late or otherwise poor diagnosis.

**"SangStat is delighted to see its complexine technology applied in the field of oncology, where it has potential for therapeutic application"** said Jean-Jacques Bienaimé, president and CEO of SangStat. "Similar licenses are now available from SangStat to other companies that have complementary technologies and desire to access the complexine technology to develop and market new therapeutics. SangStat also will be pursuing joint development opportunities with relevant companies", he continued.

"We are excited about the potential of combining SangStat technology with ours to provide more effective cancer treatment" said president and CEO of Endocyte, P. Ron Ellis. "Our preclinical data with this combination technology is very encouraging. Having this partnership with Sangstat, we will accelerate our efforts to begin human clinical trials in 2002 using this technology.

### **SangStat**

SangStat is a global biotechnology company building on its foundation in transplantation to discover, develop and market high value therapeutic products in the transplantation, immunology and hematology/oncology areas. Since 1988, SangStat has been dedicated to improving the outcome of organ and bone marrow transplantation through the development and marketing of products to address all phases of transplantation in the worldwide market. SangStat's US headquarters are in Fremont, California. SangStat also maintains a strong European presence, including direct sales and marketing forces in France, Germany, Italy, Spain, and the U.K., and distributors throughout the rest of the world. SangStat's stock is traded on the Nasdaq under the symbol "SANG". The company's web site is located at [www.sangstat.com](http://www.sangstat.com).

### **Endocyte**

Endocyte, Inc, headquartered in West Lafayette, Indiana, is a drug delivery company that utilizes vitamins to target and deliver drugs to cancer cells. Philip Low, a Purdue chemistry professor and Endocyte's chief science officer, founded the company in 1996. Endocyte has two products in human clinical trials that utilize the vitamin folate to target and deliver anticancer drugs. Endocyte's continual development is due, in part, to it's teamwork and commitment to building partnerships with innovative companies. Press releases and other corporate information can be found on Endocyte's website at [www.endocyte.com](http://www.endocyte.com).

*This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding SangStat's licensing, product development and marketing of products. Forward-looking statements reflect SangStat's current views with respect to future events. Actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated. Factors that could cause actual results to differ materially and adversely include, without limitation, failures or delays in its or its licensees' drug discovery or development programs in oncology or other indications, the failure to issue, delay of or opposition to patents, the failure or delay in obtaining other licensing or development agreements, and existing or new competition with respect to both product development and marketing of existing products or competing technologies. For a discussion of these and other factors that might result in different outcomes, see "Risk Factors" in SangStat's 2000 Annual Report on Form 10-K, its 2001 quarterly reports on Form 10-Q and other documents (including registration statements on Form S-3) filed with the Securities and Exchange Commission.*

